Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 32c, Revenues Miss
November 9, 2020 5:24 PM ESTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.42, $0.32 better than the analyst estimate of $0.10. Revenue for the quarter came in at $29.2 million versus the consensus estimate of $31.49 million.
Excluding expenses related to stock-based compensation of $1.5 million, non-GAAP1 net income for the third quarter of 2020 was $44.8 million, or $0.43 per basic and $0.42 per diluted share.This compares to non-GAAP1 net income of $14.4 million, or $0.14 per basic share and $0.13... More